Chinese Pharmaceuticals Market: Trends, Reforms, Opportunities and Revenue Prospects 2015-2025

Chinese Pharmaceuticals Market: Trends, Reforms, Opportunities and Revenue Prospects 2015-2025
Chinese Pharmaceuticals Market: Trends, Reforms, Opportunities and Revenue Prospects 2015-2025 China forms the second largest pharmaceutical market in the world, after the US, a new report by visiongain finds. However will China remain as promising after the continuing healthcare reform is finished? For instance, China has announced its regulatory framework for biosimilar approval. And prescription ...

The Prostate Cancer Therapeutics Market Forecast 2015-2025: Opportunities For Leading Companies

The Prostate Cancer Therapeutics Market Forecast 2015-2025: Opportunities For Leading Companies
Prostate Cancer Therapeutics Market definition Prostate cancer, also called carcinoma of the prostate, is a form of cancer which originates in the prostate; a walnut-shaped gland in the male reproductive system. The disease possesses the metastatic ability to spread into the bones, lymph nodes, rectum, bladder and the lower part of the ureter. However, the ...

VALEANT CONFIRMS AGREEMENT TO ACQUIRE FEMALE LIBIDO DRUG MAKER SPROUT

Valeant has arranged a $1 billion purchase of the maker of the first US-approved libido drug for women in a bet that demand for the drug will one day resemble the multibillion-dollar market to treat men’s sexual dysfunction, Bloomberg reports. This represents a risky proposition. The deal to acquire Sprout, which also includes undisclosed future ...

FORMER US PRESIDENT CARTER TREATED WITH MERCK’S KEYTRUDA

Cancer experts have expressed hope after learning that former President Jimmy Carter’s melanoma would be treated with Merck’s Keydruda, a new treatment that harnesses the body’s immune system to fight cancer, Reuters reports. In a news conference on Thursday, Carter said he was battling the deadly skin cancer melanoma, which has spread to his liver ...

NOVARTIS SKIN CANCER DRUG APPROVED IN EU

Novartis’ once-daily pill Odomzo has received European clearance for the most common type of skin cancer just weeks after being approved in the US, pharmatimes.com reports. The EC says the drug can be used to treat adult patients with locally advanced basal cell carcinoma (laBCC) who are not amenable to curative surgery or radiation therapy. ...

EMA TO REVIEW PFIZER’S IBRANCE FOR BREAST CANCER

The EMA has validated Pfizer’s application to market first-in-class Ibrance for breast cancer, clearing the final hurdle before an actual review, pharmatimes.com reports. The drug giant is seeking approval of Ibrance (palbociclib) in combination with endocrine therapy for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer. ...

NOVARTIS ACQUIRES RIGHTS TO EXPERIMENTAL MS DRUG FOR $1BN

Novartis agreed to buy the rights to an experimental multiple sclerosis drug from GSK for as much as $1 billion as it races to catch up with a competing treatment being developed by Roche, Bloomberg reports. Novartis will pay $300 million upfront to GSK for ofatumumab, followed by another $200 million after the start of ...

TAKEDA SAYS EUROPEAN REGULATORS ACCEPT MAA FOR IXAZOMIB

Takeda Pharmaceutical Company has said that the EMA has accepted the Marketing Authorisation Application or MAA for ixazomib, an investigational oral proteasome inhibitor for the treatment of patients with relapsed and/or refractory multiple myeloma, RTTNews.com reports. On 23th July, ixazomib was granted accelerated assessment by the CHMP of the EMA, a designation reserved for medicines ...

SAMSUNG BIOEPIS HIRES BANKS FOR PLANNED NASDAQ IPO

South Korea’s Samsung Bioepis, a biosimilar drug development arm of conglomerate Samsung Group, has hired four banks to manage its planned US listing next year, a person with direct knowledge of the matter said on Thursday, Reuters reports. Samsung Bioepis hired Citigroup and Goldman Sachs as the lead managers for the Nasdaq listing, the person ...

EU COMMISSION CLEARS PERRIGO TO ACQUIRE GSK UNITS

The EC cleared on Friday US drug maker Perrigo’s acquisition of certain assets from Britain’s GSK, Reuters reports. The Commission, in its role as the competition regulator in the 28-member EU, said GSK would sell certain products such as cold and flu drugs, cold sore and pain treatment products to Perrigo. “The proposed acquisition would ...